Occupational Therapists in Stanwood, WA Accepting Medicare
7 Occupational Therapists found. Showing 1 - 7
 Mr. Jeff G Stinardo, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 18514 40th Ave Nw, Stanwood, WA 98292 Phone: 360-652-2632 Fax: 360-652-2623 |
 Bailey Bartelt Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9901 272nd Pl Nw, Stanwood, WA 98292 Phone: 360-386-3230 |
Diane M Spotts Occupational Therapist Medicare: Medicare Enrolled Practice Location: 9901 272nd Pl Nw, Stanwood, WA 98292 Phone: 360-386-3111 |
Mrs. Kathleen A. Klingenberg, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 10227 273rd Pl Nw, Stanwood, WA 98292 Phone: 360-629-1250 Fax: 360-629-1252 |
Walker Lee Bassett, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 20420 Marine Dr, Stanwood, WA 98292 Phone: 360-652-7585 |
Ashley Willie Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9901 272nd Pl Nw, Stanwood, WA 98292 Phone: 360-629-2126 |
Ms. Jill M Anderson, OTR/L, CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 27500 102nd Ave Nw Ste 1, Stanwood, WA 98292 Phone: 360-629-9768 Fax: 360-629-6487 |
News Archive
Polyamine-deficient diets effective as pain relief treatment for chronic and acute pain
Before and after spinal surgery, patients on a polyamine-deficient diets experienced significant relief of both chronic and acute pain, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
Research progress with promising Alzheimer's drug Xanamem
Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer's disease and other major age-related neurodegenerative disorders, is pleased to announce that it has received ethics approval to initiate the third and final stage of the second Phase I trial of its lead Alzheimer's drug candidate, Xanamem™.
Catalyst Pharmaceutical raises $3.97 million from institutional investors
Catalyst Pharmaceutical Partners, Inc. today announced that it has closed its previously announced registered direct offering of 3.97 million shares of its common stock to institutional investors at a price per share of $1.00, representing gross proceeds of $3.97 million.
Membrane distillation plants provide water for the world's poorest
Lack of water causes great distress among the population in large parts of Africa and Asia. Small decentralized water treatment plants with an autonomous power supply can help solve the problem: They transform salty seawater or brackish water into pure drinking water.
› Verified 4 days ago
Physical Therapists
Chiropractors
Optometrists
Occupational Therapists
Speech-Language Pathologists
Audiologists